

Jinsoo Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8259103/publications.pdf>

Version: 2024-02-01

78
papers

915
citations

471509

17
h-index

580821

25
g-index

79
all docs

79
docs citations

79
times ranked

1445
citing authors

#	ARTICLE	IF	CITATIONS
1	De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 25-33.	0.1	0
2	A Machine Learning Approach to Predict the Probability of Brain Metastasis in Renal Cell Carcinoma Patients. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 6174.	2.5	3
3	Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity score-matched study using the Korean Renal Cancer Study Group database. <i>International Journal of Urology</i> , 2021, 28, 417-423.	1.0	3
4	Prognostic significance of pathologic nodal positivity in non-metastatic patients with renal cell carcinoma who underwent radical or partial nephrectomy. <i>Scientific Reports</i> , 2021, 11, 3079.	3.3	1
5	Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 570077.	2.8	9
6	A Retrospective, Multicenter, Long-Term Follow-Up Analysis of the Prognostic Characteristics of Recurring Non-Metastatic Renal Cell Carcinoma After Partial or Radical Nephrectomy. <i>Frontiers in Oncology</i> , 2021, 11, 653002.	2.8	4
7	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26826.	1.0	2
8	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 187-196.	2.5	24
9	The prognostic role of preoperative serum albumin/globulin ratio in patients with non-metastatic renal cell carcinoma undergoing partial or radical nephrectomy. <i>Scientific Reports</i> , 2020, 10, 11999.	3.3	15
10	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. <i>Investigative and Clinical Urology</i> , 2020, 61, 260.	2.0	5
11	The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. <i>Investigative and Clinical Urology</i> , 2020, 61, 475.	2.0	7
12	Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study. <i>Investigative and Clinical Urology</i> , 2020, 61, 146.	2.0	0
13	Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray. <i>Investigative and Clinical Urology</i> , 2020, 61, 372.	2.0	3
14	Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2019, 19, 688.	2.6	5
15	Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 859.	2.8	25
16	A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 413.	2.8	22
17	<i>SETD2</i> , <i>GIGYF2</i> , <i>FGFR3</i> , <i>BCR</i> , <i>KMT2C</i> , and <i>TSC2</i> as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change. <i>Investigative and Clinical Urology</i> , 2019, 60, 148.	2.0	10
18	Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. <i>Cancer Medicine</i> , 2019, 8, 3401-3410.	2.8	13

#	ARTICLE	IF	CITATIONS
19	Correlation Analyses of Computed Tomography and Magnetic Resonance Imaging for Calculation of Prostate Volume in Colorectal Cancer Patients with Voiding Problems Who Cannot Have Transrectal Ultrasonography. <i>BioMed Research International</i> , 2019, 2019, 1-8.	1.9	1
20	Single-Center Analysis of Human Papillomavirus Infection and P16INK4A Expression among Korean Patients with Penile Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-7.	1.9	1
21	Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. <i>PLoS ONE</i> , 2019, 14, e0211105.	2.5	7
22	Tumour heterogeneity in triplet-paired metastatic tumour tissues in metastatic renal cell carcinoma: concordance analysis of target gene sequencing data. <i>Journal of Clinical Pathology</i> , 2019, 72, 152-156.	2.0	6
23	Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. <i>Investigative and Clinical Urology</i> , 2019, 60, 432.	2.0	6
24	Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 910-918.	3.0	2
25	Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. <i>Cancer Research and Treatment</i> , 2019, 51, 758-768.	3.0	9
26	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. <i>Investigative and Clinical Urology</i> , 2019, 60, 184.	2.0	2
27	Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. <i>Scientific Reports</i> , 2018, 8, 2974.	3.3	4
28	Renal capsular invasion is a prognostic biomarker in localized clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2018, 8, 202.	3.3	10
29	The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2018, 2018, 1-8.	1.3	9
30	Clear cell papillary renal cell carcinoma: A case report and review of the literature. <i>World Journal of Nephrology</i> , 2018, 7, 155-160.	2.0	1
31	Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. <i>Journal of Korean Medical Science</i> , 2018, 33, e325.	2.5	13
32	Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching. <i>BioMed Research International</i> , 2018, 2018, 1-7.	1.9	9
33	Partial versus Radical Nephrectomy for T1-T2 Renal Cell Carcinoma in Patients with Chronic Kidney Disease Stage III: a Multiinstitutional Analysis of Kidney Function and Survival Rate. <i>Journal of Korean Medical Science</i> , 2018, 33, e277.	2.5	7
34	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. <i>Nutrition and Cancer</i> , 2018, 70, 886-894.	2.0	18
35	A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia. <i>Case Reports in Urology</i> , 2018, 2018, 1-4.	0.3	2
36	Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. <i>Journal of Surgical Oncology</i> , 2018, 118, 199-205.	1.7	9

#	ARTICLE	IF	CITATIONS
37	The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. Japanese Journal of Clinical Oncology, 2018, 48, 835-840.	1.3	8
38	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of Hematology and Oncology, 2018, 11, 69.	17.0	32
39	Prostate stem cell antigen mRNA in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer. Oncotarget, 2018, 9, 26291-26298.	1.8	3
40	Retrospective analysis of 25 immunohistochemical tissue markers for differentiating multilocular cystic renal neoplasm of low malignant potential and multicystic renal cell carcinoma. Histology and Histopathology, 2018, 33, 589-596.	0.7	5
41	The effect of predisposing atheroembolic risk factors on renal functional recovery between laparoscopy and open technique in patients with T1-stage renal cell carcinoma who underwent partial nephrectomy: a retrospective comparison study. Japanese Journal of Clinical Oncology, 2017, 47, 876-882.	1.3	1
42	Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. BMC Cancer, 2017, 17, 364.	2.6	17
43	Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer, 2017, 15, 100-111.	1.9	28
44	Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International, 2017, 2017, 1-13.	1.9	4
45	Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. BioMed Research International, 2017, 2017, 1-9.	1.9	6
46	Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. Journal of Korean Medical Science, 2017, 32, 377.	2.5	11
47	Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea. Cancer Research and Treatment, 2017, 49, 607-615.	3.0	30
48	The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry. PLoS ONE, 2017, 12, e0179610.	2.5	48
49	Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget, 2017, 8, 64449-64458.	1.8	6
50	A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. Oncotarget, 2017, 8, 93633-93643.	1.8	13
51	Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients. Oncotarget, 2017, 8, 96117-96125.	1.8	3
52	Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison. Oncotarget, 2017, 8, 100056-100065.	1.8	5
53	Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naA ^{ve} , unresectable metastatic renal cell carcinoma. PLoS ONE, 2017, 12, e0177975.	2.5	2
54	The establishment of KORCC (Korean Renal Cell Carcinoma) database. Investigative and Clinical Urology, 2016, 57, 50.	2.0	30

#	ARTICLE	IF	CITATIONS
55	A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma. <i>Journal of Korean Medical Science</i> , 2016, 31, 1983.	2.5	3
56	Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	20
57	Baseline Chronic Kidney Disease and Ischemic Method of Partial Nephrectomy Are Important Factors for the Short- and Long-Term Deterioration in Renal Function for Renal Cell Carcinoma Staged T1-T2: A Retrospective Single Center Study. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	3
58	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. <i>Journal of Korean Medical Science</i> , 2016, 31, 1976.	2.5	20
59	A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. <i>BMC Cancer</i> , 2016, 16, 577.	2.6	4
60	Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy. <i>PLoS ONE</i> , 2016, 11, e0151646.	2.5	5
61	The Correlation of Tissue-Based Biomarkers in Primary and Metastatic Renal Cell Carcinoma Lesions: A Tissue Microarray Study. <i>The Korean Journal of Urological Oncology</i> , 2016, 14, 152-158.	0.1	4
62	A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. <i>Cancer Research and Treatment</i> , 2016, 48, 838-842.	3.0	4
63	Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. <i>Cancer Research and Treatment</i> , 2016, 48, 1092-1101.	3.0	24
64	Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0122498.	2.5	45
65	Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients. <i>Prostate International</i> , 2015, 3, 56-61.	2.3	6
66	The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer. <i>BMC Urology</i> , 2015, 15, 82.	1.4	7
67	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. <i>PLoS ONE</i> , 2015, 10, e0135165.	2.5	5
68	Low C24â€œOH and C22â€œOH sulfatides in human renal cell carcinoma. <i>Journal of Mass Spectrometry</i> , 2014, 49, 409-416.	1.6	8
69	Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. <i>Annals of Surgical Oncology</i> , 2013, 20, 4397-4404.	1.5	34
70	Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma. <i>Korean Journal of Urology</i> , 2012, 53, 217.	1.2	49
71	Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. <i>Cancer</i> , 2010, 116, 2332-2342.	4.1	51
72	Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 145-148.	1.7	26

#	ARTICLE	IF	CITATIONS
73	Prostate Specific Membrane Antigen mRNA in Blood as a Potential Predictor of Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Korean Medical Science</i> , 2010, 25, 1291.	2.5	8
74	Familial Prostate Cancer in Three Brothers. <i>Korean Journal of Urology</i> , 2009, 50, 195.	1.2	1
75	The efficacy of transureteroureterostomy for ureteral reconstruction during surgery for a nonurologic pelvic malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 49-53.	1.7	14
76	Epidermal Growth Factor Receptor as Predicting Factor on Biochemical Recurrence after Radical Prostatectomy: A Prospective Study. <i>Korean Journal of Urology</i> , 2008, 49, 974.	0.2	7
77	Partial Nephrectomy using Parenchymal Compression without Renal Pedicle Clamping. <i>Korean Journal of Urology</i> , 2007, 48, 265.	0.2	2
78	Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. <i>Cancer Letters</i> , 2004, 203, 155-161.	7.2	39